HC Wainwright Issues Negative Outlook for VNDA Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.52) per share for the quarter, down from their prior forecast of ($0.13). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at $0.22 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million.

Separately, StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $4.43 on Thursday. Vanda Pharmaceuticals has a fifty-two week low of $3.71 and a fifty-two week high of $6.75. The company has a 50 day simple moving average of $4.60 and a two-hundred day simple moving average of $4.82. The company has a market capitalization of $258.36 million, a price-to-earnings ratio of -13.84 and a beta of 0.74.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after purchasing an additional 227,428 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company’s stock worth $6,949,000 after acquiring an additional 24,483 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 4.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock worth $3,925,000 after acquiring an additional 38,449 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Vanda Pharmaceuticals by 1.4% during the 4th quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company’s stock worth $3,481,000 after acquiring an additional 9,840 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 67.4% during the 4th quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after acquiring an additional 269,183 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.